CN100357279C - 缬沙坦的制备方法 - Google Patents

缬沙坦的制备方法 Download PDF

Info

Publication number
CN100357279C
CN100357279C CNB038245140A CN03824514A CN100357279C CN 100357279 C CN100357279 C CN 100357279C CN B038245140 A CNB038245140 A CN B038245140A CN 03824514 A CN03824514 A CN 03824514A CN 100357279 C CN100357279 C CN 100357279C
Authority
CN
China
Prior art keywords
formula
compound
alkyl
methyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038245140A
Other languages
English (en)
Chinese (zh)
Other versions
CN1688556A (zh
Inventor
D·登尼-迪斯舍尔
H·希尔特
D·内维尔
G·塞德尔迈耶
A·施奈德尔
N·德里安
D·考夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944606&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100357279(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1688556A publication Critical patent/CN1688556A/zh
Application granted granted Critical
Publication of CN100357279C publication Critical patent/CN100357279C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CNB038245140A 2002-09-23 2003-09-22 缬沙坦的制备方法 Expired - Fee Related CN100357279C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0222056.4 2002-09-23
GBGB0222056.4A GB0222056D0 (en) 2002-09-23 2002-09-23 Process for the manufacture of organic compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2007101692527A Division CN101153027B (zh) 2002-09-23 2003-09-22 缬沙坦的制备方法

Publications (2)

Publication Number Publication Date
CN1688556A CN1688556A (zh) 2005-10-26
CN100357279C true CN100357279C (zh) 2007-12-26

Family

ID=9944606

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB038245140A Expired - Fee Related CN100357279C (zh) 2002-09-23 2003-09-22 缬沙坦的制备方法
CN2007101692527A Expired - Fee Related CN101153027B (zh) 2002-09-23 2003-09-22 缬沙坦的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2007101692527A Expired - Fee Related CN101153027B (zh) 2002-09-23 2003-09-22 缬沙坦的制备方法

Country Status (29)

Country Link
US (3) US20060069268A1 (enExample)
EP (2) EP1878729A1 (enExample)
JP (2) JP4787498B2 (enExample)
KR (2) KR20050057529A (enExample)
CN (2) CN100357279C (enExample)
AR (1) AR041360A1 (enExample)
AU (1) AU2003270241B2 (enExample)
BR (1) BR0314132A (enExample)
CA (1) CA2502629A1 (enExample)
CY (1) CY1107878T1 (enExample)
DE (1) DE60317690T2 (enExample)
DK (1) DK1546122T3 (enExample)
EC (2) ECSP055695A (enExample)
ES (1) ES2295623T3 (enExample)
GB (1) GB0222056D0 (enExample)
IL (1) IL167426A (enExample)
MX (1) MXPA05003140A (enExample)
MY (1) MY138618A (enExample)
NO (2) NO20051970L (enExample)
NZ (2) NZ538927A (enExample)
PE (2) PE20050088A1 (enExample)
PL (1) PL374862A1 (enExample)
PT (1) PT1546122E (enExample)
RU (2) RU2348619C2 (enExample)
SG (1) SG155049A1 (enExample)
SI (1) SI1546122T1 (enExample)
TW (2) TWI329106B (enExample)
WO (1) WO2004026847A1 (enExample)
ZA (1) ZA200502159B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
TW200505879A (en) 2003-04-21 2005-02-16 Teva Pharma Process for the preparation of valsartan
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
EP1661891A1 (en) * 2004-11-30 2006-05-31 KRKA, D.D., Novo Mesto A process for the synthesis of valsartan
GB0514206D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
ES2288376B1 (es) * 2005-10-20 2008-11-01 Inke, S.A. Procedimiento para la obtencion de intermedios utiles en la obtencion de un compuesto farmaceuticamente activo.
WO2007057919A2 (en) * 2005-10-25 2007-05-24 Alembic Limited An improved process for preparation of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine
EP2057132A2 (en) * 2006-07-03 2009-05-13 Aurobindo Pharma Limited Process for the preparation of the angiotensin ii antagonist valsartan
ES2315141B1 (es) * 2006-11-23 2009-12-22 Quimica Sintetica, S.A Procedimiento para la preparacion de cardesartan cilexetilo en forma cristalina.
CN101200455B (zh) * 2007-09-29 2010-08-18 泰兴市江神化工有限公司 沙坦类治疗高血压药物主环5-(4'-甲酰基联苯-2-基)-1h-四氮唑的制备方法
US7943794B2 (en) * 2008-02-13 2011-05-17 Ranbaxy Laboratories Limited Processes for the preparation of intermediates of valsartan
KR101012135B1 (ko) * 2008-12-18 2011-02-07 주식회사 대희화학 발사르탄 메틸 에스테르의 제조방법
EP2316821A1 (en) 2009-10-27 2011-05-04 Novartis AG Process for the manufacture of organic compounds
AR082435A1 (es) * 2010-08-03 2012-12-05 Novartis Ag Valsartan altamente cristalino
CN102351804B (zh) * 2011-09-30 2013-07-31 浙江新赛科药业有限公司 一种缬沙坦消旋体的回收方法
CN103554047A (zh) * 2013-10-11 2014-02-05 镇江市高等专科学校 制备缬沙坦的方法
CN103923028B (zh) * 2014-05-04 2017-05-24 青岛雪洁助剂有限公司 一种缬沙坦甲酯的制备方法
CN104072433A (zh) * 2014-07-16 2014-10-01 南京正大天晴制药有限公司 一种缬沙坦的水解杂质化合物及其制备方法、检测方法和用途
CN104151199A (zh) * 2014-08-13 2014-11-19 苏州卫生职业技术学院 一种缬沙坦的合成方法
CN104844476B (zh) * 2015-04-03 2016-08-24 李凌 一种医药中间体联苯类化合物的合成方法
CN112014479A (zh) * 2019-05-28 2020-12-01 珠海润都制药股份有限公司 一种缬沙坦中正戊酰氯的检测方法
CN116655498B (zh) * 2023-05-24 2025-01-28 江苏阿尔法集团福瑞药业(宿迁)有限公司 一种沙库巴曲中间体的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1149294A (zh) * 1994-05-27 1997-05-07 森德克斯(美国)股份有限公司 1-丁基-2-[2-(2h-四唑-5-基)-联苯-4-基甲基)-1h-吲哚-3-羧酸的制备方法
US5965592A (en) * 1990-02-19 1999-10-12 Novartis Corporation Acyl compounds
CN1317485A (zh) * 2000-04-07 2001-10-17 常州四药制药有限公司 一种合成缬沙坦的改进方法
WO2002006253A1 (en) * 2000-07-19 2002-01-24 Novartis Ag Valsartan salts

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820843A (en) * 1987-05-22 1989-04-11 E. I. Du Pont De Nemours And Company Tetrazole intermediates to antihypertensive compounds
US5260325A (en) * 1991-08-19 1993-11-09 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking tertiary amides
EP0550313A1 (fr) * 1991-12-30 1993-07-07 Synthelabo Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse
FR2688503B1 (fr) * 1992-03-16 1994-05-06 Synthelabo Procede de preparation de derives de 2-(tetrazol-5-yl)-[1,1'-biphenyle].
US5284957A (en) * 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
JPH08165292A (ja) * 1993-10-07 1996-06-25 Techno Res Kk アデニン誘導体、その製造法及び用途
US5412102A (en) * 1994-05-27 1995-05-02 Syntex (U.S.A.) Inc. Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
DK0782996T3 (da) * 1994-09-20 1999-09-20 Wakunaga Seiyaku Kk Fremgangsmåde til fremstilling af N-biphenylmethylthiadiazolinderivat eller salt deraf og mellemprodukt til fremstilling af
CA2223783A1 (en) * 1995-06-07 1996-12-19 Michel Bernatchez Process for preparation of biphenyl derivatives
US6071931A (en) * 1995-10-06 2000-06-06 Novartis Ag AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
JP4537678B2 (ja) * 2003-09-04 2010-09-01 住友化学株式会社 ２’−（１ｈ−テトラゾール−５−イル）ビフェニル−４−カルボアルデヒド結晶およびその製造方法
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965592A (en) * 1990-02-19 1999-10-12 Novartis Corporation Acyl compounds
CN1149294A (zh) * 1994-05-27 1997-05-07 森德克斯(美国)股份有限公司 1-丁基-2-[2-(2h-四唑-5-基)-联苯-4-基甲基)-1h-吲哚-3-羧酸的制备方法
CN1317485A (zh) * 2000-04-07 2001-10-17 常州四药制药有限公司 一种合成缬沙坦的改进方法
WO2002006253A1 (en) * 2000-07-19 2002-01-24 Novartis Ag Valsartan salts

Also Published As

Publication number Publication date
US20090111995A1 (en) 2009-04-30
ECSP055695A (es) 2005-05-30
JP2006502178A (ja) 2006-01-19
TW200413337A (en) 2004-08-01
JP4787498B2 (ja) 2011-10-05
WO2004026847A1 (en) 2004-04-01
JP2010254709A (ja) 2010-11-11
HK1079771A1 (en) 2006-04-13
US20060069268A1 (en) 2006-03-30
SI1546122T1 (sl) 2008-04-30
EP1546122B8 (en) 2008-05-28
EP1878729A1 (en) 2008-01-16
GB0222056D0 (en) 2002-10-30
DE60317690D1 (de) 2008-01-03
AU2003270241A1 (en) 2004-04-08
RU2348619C2 (ru) 2009-03-10
ZA200502159B (en) 2005-09-21
PE20091387A1 (es) 2009-10-13
US20100249429A1 (en) 2010-09-30
NO20110856L (no) 2005-06-16
AU2003270241B2 (en) 2007-08-23
CN101153027A (zh) 2008-04-02
RU2412173C2 (ru) 2011-02-20
ECSP105695A (es) 2010-03-31
TW201016673A (en) 2010-05-01
EP1546122A1 (en) 2005-06-29
PL374862A1 (en) 2005-11-14
RU2005112444A (ru) 2006-01-20
PT1546122E (pt) 2008-02-14
MXPA05003140A (es) 2005-06-22
CA2502629A1 (en) 2004-04-01
CN1688556A (zh) 2005-10-26
IL167426A (en) 2010-11-30
DE60317690T2 (de) 2008-10-30
ES2295623T3 (es) 2008-04-16
KR20050057529A (ko) 2005-06-16
EP1546122B1 (en) 2007-11-21
DK1546122T3 (da) 2008-03-03
MY138618A (en) 2009-07-31
KR20110015703A (ko) 2011-02-16
TWI338003B (en) 2011-03-01
TWI329106B (en) 2010-08-21
RU2008133680A (ru) 2010-02-27
NO20051970L (no) 2005-06-16
CY1107878T1 (el) 2013-06-19
SG155049A1 (en) 2009-09-30
NZ566863A (en) 2009-08-28
NZ538927A (en) 2008-05-30
BR0314132A (pt) 2005-06-28
AR041360A1 (es) 2005-05-11
PE20050088A1 (es) 2005-02-21
CN101153027B (zh) 2010-08-18

Similar Documents

Publication Publication Date Title
CN100357279C (zh) 缬沙坦的制备方法
CN100537538C (zh) 用于制备喜树碱衍生物（cpt-11）以及相关化合物的中间体和方法
US5412102A (en) Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid
JPH05271205A (ja) ２−（テトラゾール−５−イル）−１，１’−ビフェニル誘導体、その製造法および合成中間体としての使用
CN1958593B (zh) 一种用于合成瑞舒伐他汀钙的中间体的制备方法
KR19990022528A (ko) 비페닐 유도체의 제조방법
US5977372A (en) Chloro or bromo[2-[2-(tert-butyl)-2H-tetrazol-5-yl]phenyl]zinc intermediates
CN109761884A (zh) 一种手性胺b的制备方法及其应用
CN101133035A (zh) 制备洛沙坦的方法
JPH069625A (ja) ４−ピリミジノン類の新規製造法
JPH10501229A (ja) １−ブチル−２−［２’−（２ｈ−テトラゾル−５−イル）−ビフェニル−４−イルメチル］−１ｈ−インドール−３−カルボン酸の製法
WO2007005967A2 (en) Process for preparing valsartan
HU226806B1 (en) Method of manufacturing the cycloheptimidazole derivatives and the used intermediates
HK1110599A (en) Intermediate for the manufacture of valsartan
JP2000273062A (ja) ハイドロキノン類の製造方法
IL131709A (en) Processes for preparing 1-butyl-2- [2'- (2h-tetrazol-5-yl) biphenyl-4-ylmethyl]-1h-indole-3-carboxylic acid
NO742234L (enExample)
HK1079771B (en) Process for the manufacture of valsartan
JPS59106475A (ja) テトラゾ−ル誘導体及びその製法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20071226

Termination date: 20120922